FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2019994508> ?p ?o ?g. }

• W2019994508 endingPage "296" @default.
• W2019994508 startingPage "293" @default.
• W2019994508 abstract "Since the implementation of a biosimilar approval pathway in 2005, several biosimilars including somatotropins, filgrastims and epoietins have been approved and become available in Europe on the basis of comparable quality, safety and efficacy to the originator product (Weise et al, 2012). However, there is still general skepticism in the scientific community about the safety and efficacy of biosimilar granulocyte-colony stimulating factors (G-CSF). The use of G-CSF as a supportive therapy after autologous haematopoietic stem cell transplantation (ASCT) is able to reduce the time of neutrophilis recovery and the incidence of febrile neutropenia and infectious episodes. For this reason, the American Society of Clinical Oncology (ASCO) and the European Group for Blood and Marrow Transplantation recommended the use of G-CSF after ASCT (Smith et al, 2006; Apperley et al, 2008). So far, only limited data have been published regarding the use of biosimilar filgrastim in haematological recovery after ASCT (Ferro et al, 2009; Niederwieser & Schmitz, 2011; Ianotto et al, 2012; Reményi et al, 2014). Despite limitations due to retrospective analyses performed on limited numbers of patients, all these studies suggest a substantially similar efficacy of biosimilar products, when compared to originators for prophylaxis of febrile neutropenia in lymphoma and myeloma patients post-ASCT. From March 2013 to June 2014, our Institution used the biosimilar filgrastim (Zarzio®; Sandoz Industrial Products, Rovereto, Italy), at dosage of 5 μg/kg/d from day +3 after stem cell infusion, for febrile neutropenia prophylaxis and haematological recovery in 64 consecutive adult patients who underwent ASCT. These patients were retrospectively compared with three historical cohorts: (i) 99 consecutive adult patients treated with lenograstim (Myelostim®; Italfarmaco, Milan, Italy) at dosage of 5 μg/kg/d from day +3 after stem cell infusion at our Institution from January 2009 to February 2013; (ii) 60 consecutive adult patients treated with peg-filgrastim (Neulasta®; Amgen, Milan, Italy) at a single dose of 6 mg at day +3 after stem cell infusion at our Institution from March 2006 to December 2008; (iii) 79 consecutive adult patients treated with originator filgrastim (Granulokine®; Amgen) at dosage of 5 μg/kg/d from day +3 after stem cell infusion at the Haematology Unit of Campus Bio-Medico University from May 2008 to June 2014. This study aimed to compare Zarzio® with the other available formulations of G-CSF in terms of efficacy and safety. Baseline features of 302 patients are summarized in Table 1. There was no statistically significant difference among the four patient cohorts, despite an higher incidence of lymphomas in the group of patients treated with Neulasta® (P = 0·074). In particular, the number of infused CD34+ cells was similar in each cohort (P = 0·834). We analysed the period of haematological recovery after stem cell infusion (defined as an absolute neutrophilis count >0·5 × 109/l and a platelet count >20 × 109/l for three consecutive checks), the occurrence of fever of unknown origin (FUO) in neutropenia, documented infectious episodes and need of intravenous antibiotic treatment, number of red blood and platelet transfusions, days of hospitalization and transplant-related mortality (TRM). The results of the study are shown in Table 2. We observed a significantly shorter time to neutrophilis and platelet recovery (P = 0·001 and P = 0·007, respectively) with a consequent lower median number of platelet transfusions (P = 0·001) in the cohort of patients treated with Neulasta®, whereas no difference was observed among the other three groups. Moreover, we did not observe any significant difference among the four patient cohorts for all the other analysed parameters, despite a trend for a shorter period of hospitalization in the patients treated with Zarzio® and Neulasta® (P = 0·095). No difference in terms of drug-related adverse events was observed in the four patient cohorts with no serious adverse events. Similar results were obtained when two separate sub-analyses including only lymphoma or myeloma patients were performed (data not shown). Our study shows that biosimilar filgrastim (Zarzio®) has similar efficacy and safety when compared with the other non-peghylated G-CSF formulations in febrile neutropenia prophylaxis and haematological recovery after ASCT. These data confirm previous published evidence that supports the non-inferiority of biosimilar filgrastim in this setting (Ferro et al, 2009; Niederwieser & Schmitz, 2011; Ianotto et al, 2012; Reményi et al, 2014). Moreover, although some preclinical studies highlighted the better efficacy of neutrophilis after stimulation with lenograstim than filgrastim (Ribeiro et al, 2007), we did not find any significant difference between glycosylated and not-glycosylated G-CSF formulations regarding FUO in neutropenia and occurrence of infections, according to the current ASCO guidelines (Smith et al, 2006) and European Organization for Research and Treatment of Cancer (Aapro et al, 2011). Some recently published data also showed that peg-filgrastim presents similar efficacy and safety profiles when compared with non-pegylated formulations after ASCT (Sebban et al, 2012). Despite the limitation due to its retrospective nature, our study suggests a significantly better time to neutrophilis and platelet recovery in patients treated with peg-filgrastim (Neulasta®). However, this superiority does not determine a better outcome in terms of FUO in neutropenia and infectious episodes, duration of hospitalization and TRM, but only a significant decrease in platelet transfusions. Biosimilar products are characterized by a different method of synthesis compared to originators, because they utilize bacterial support (Weise et al, 2012). This method induces some modifications of the molecules but permits generation of a final product similar to the originator drug with a significant limitation of the costs. Based on this premise, we also analysed the costs relative to G-CSF administration. Considering the median days of G-CSF injections and assuming a patient median body weight of 60 kg, the estimated cost for each patient was significantly lower in the Zarzio® group (approximately 73€) when compared with the other groups (approximately 732€ for Myelostim®, 649€ for Granulokine® and 660€ for Neulasta®; P < 0·0001). In conclusion, our retrospective analysis indicates that biosimilar filgrastim (Zarzio®) seems to be substantially equivalent in terms of efficacy and safety to other G-CSF formulations when used for febrile neutropenia prophylaxis and haematological recovery after ASCT in adult patients with haematological malignancies. However, the use of biosimilar filgrastim results in significantly lower costs in this setting. Further prospective randomized studies are warranted to confirm these results. We thanks Mrs. Caterina Viggiani for data collection about hospitalization duration. The authors declare no financial or other potential conflicts of interest. Concept and design of the study: F.M., A.M.; clinical management and data collection: F.M., E.C., M.L.D., S.G., L.F., F.P., F.P., A.R., A.S., L.P., O.A., A.L.M.; data analysis and interpretation: F.M., A.M.; manuscript writing: F.M.; final critical revision of the manuscript: W.A., A.M." @default.
• W2019994508 created "2016-06-24" @default.
• W2019994508 creator A5008447915 @default.
• W2019994508 creator A5014371750 @default.
• W2019994508 creator A5014587746 @default.
• W2019994508 creator A5017014344 @default.
• W2019994508 creator A5037076561 @default.
• W2019994508 creator A5047010545 @default.
• W2019994508 creator A5049597727 @default.
• W2019994508 creator A5052928168 @default.
• W2019994508 creator A5065997839 @default.
• W2019994508 creator A5066769957 @default.
• W2019994508 creator A5071289483 @default.
• W2019994508 creator A5086803832 @default.
• W2019994508 creator A5087930234 @default.
• W2019994508 creator A5005864660 @default.
• W2019994508 date "2014-11-05" @default.
• W2019994508 modified "2023-09-27" @default.
• W2019994508 title "Comparison between biosimilar filgrastim vs other granulocyte-colony stimulating factor formulations (originator filgrastim, peg-filgrastim and lenograstim) after autologous stem cell transplantation: a retrospective survey from the Rome Transplant Networ" @default.
• W2019994508 cites W1971471395 @default.
• W2019994508 cites W1996335228 @default.
• W2019994508 cites W2003924403 @default.
• W2019994508 cites W2063608974 @default.
• W2019994508 cites W2068028000 @default.
• W2019994508 cites W2137516815 @default.
• W2019994508 cites W2142195688 @default.
• W2019994508 cites W2142289247 @default.
• W2019994508 cites W2169403306 @default.
• W2019994508 doi "https://doi.org/10.1111/bjh.13199" @default.
• W2019994508 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25371286" @default.
• W2019994508 hasPublicationYear "2014" @default.
• W2019994508 type Work @default.
• W2019994508 sameAs 2019994508 @default.
• W2019994508 citedByCount "8" @default.
• W2019994508 countsByYear W20199945082015 @default.
• W2019994508 countsByYear W20199945082016 @default.
• W2019994508 countsByYear W20199945082018 @default.
• W2019994508 countsByYear W20199945082021 @default.
• W2019994508 crossrefType "journal-article" @default.
• W2019994508 hasAuthorship W2019994508A5005864660 @default.
• W2019994508 hasAuthorship W2019994508A5008447915 @default.
• W2019994508 hasAuthorship W2019994508A5014371750 @default.
• W2019994508 hasAuthorship W2019994508A5014587746 @default.
• W2019994508 hasAuthorship W2019994508A5017014344 @default.
• W2019994508 hasAuthorship W2019994508A5037076561 @default.
• W2019994508 hasAuthorship W2019994508A5047010545 @default.
• W2019994508 hasAuthorship W2019994508A5049597727 @default.
• W2019994508 hasAuthorship W2019994508A5052928168 @default.
• W2019994508 hasAuthorship W2019994508A5065997839 @default.
• W2019994508 hasAuthorship W2019994508A5066769957 @default.
• W2019994508 hasAuthorship W2019994508A5071289483 @default.
• W2019994508 hasAuthorship W2019994508A5086803832 @default.
• W2019994508 hasAuthorship W2019994508A5087930234 @default.
• W2019994508 hasBestOaLocation W20199945081 @default.
• W2019994508 hasConcept C126322002 @default.
• W2019994508 hasConcept C143998085 @default.
• W2019994508 hasConcept C2776694085 @default.
• W2019994508 hasConcept C2777408962 @default.
• W2019994508 hasConcept C2777767877 @default.
• W2019994508 hasConcept C2777983669 @default.
• W2019994508 hasConcept C2779050716 @default.
• W2019994508 hasConcept C2779171977 @default.
• W2019994508 hasConcept C2911091166 @default.
• W2019994508 hasConcept C59491497 @default.
• W2019994508 hasConcept C71924100 @default.
• W2019994508 hasConceptScore W2019994508C126322002 @default.
• W2019994508 hasConceptScore W2019994508C143998085 @default.
• W2019994508 hasConceptScore W2019994508C2776694085 @default.
• W2019994508 hasConceptScore W2019994508C2777408962 @default.
• W2019994508 hasConceptScore W2019994508C2777767877 @default.
• W2019994508 hasConceptScore W2019994508C2777983669 @default.
• W2019994508 hasConceptScore W2019994508C2779050716 @default.
• W2019994508 hasConceptScore W2019994508C2779171977 @default.
• W2019994508 hasConceptScore W2019994508C2911091166 @default.
• W2019994508 hasConceptScore W2019994508C59491497 @default.
• W2019994508 hasConceptScore W2019994508C71924100 @default.
• W2019994508 hasIssue "2" @default.
• W2019994508 hasLocation W20199945081 @default.
• W2019994508 hasLocation W20199945082 @default.
• W2019994508 hasOpenAccess W2019994508 @default.
• W2019994508 hasPrimaryLocation W20199945081 @default.
• W2019994508 hasRelatedWork W1861808521 @default.
• W2019994508 hasRelatedWork W2019994508 @default.
• W2019994508 hasRelatedWork W2106471590 @default.
• W2019994508 hasRelatedWork W2277325425 @default.
• W2019994508 hasRelatedWork W2527816261 @default.
• W2019994508 hasRelatedWork W2559911792 @default.
• W2019994508 hasRelatedWork W2790048609 @default.
• W2019994508 hasRelatedWork W3010100147 @default.
• W2019994508 hasRelatedWork W3159332416 @default.
• W2019994508 hasRelatedWork W4301697663 @default.
• W2019994508 hasVolume "169" @default.
• W2019994508 isParatext "false" @default.
• W2019994508 isRetracted "false" @default.
• W2019994508 magId "2019994508" @default.
• W2019994508 workType "article" @default.